Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison of two-year outcomes after photodynamic therapy with ranibizumab or aflibercept for polypoidal choroidal vasculopathy.

Scientific reports - 28 Nov 2017

Kikushima Wataru, Sakurada Yoichi, Sugiyama Atsushi, Yoneyama Seigo, Tanabe Naohiko, Matsubara Mio, Mabuchi Fumihiko, Iijima Hiroyuki

Abstract excerpt

Photodynamic therapy (PDT) combined with intravitreal anti-vascular endothelial growth factor (VEGF) agents is currently the first-line treatment for polypoidal choroidal vasculopathy (PCV), along with anti-VEGF monotherapy. In this study, 100 eyes with treatment-naïve PCV were initially treated with PDT combined with intravitreal ranibizumab (IVR; n = 57) or aflibercept (IVA; n = 43). We compared two-year...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Choroidal Neovascularization
Share to Follow-Up Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kaplan-Meier Estimate

Share to Photochemotherapy

Share to Receptors, Vascular Endothelial Growth Factor

Share to Recombinant Fusion Proteins

Share to Retina

Share to Visual Acuity

Source

Open in PubMed Open full text

Identifiers

PMID: 29184088
DOI: 10.1038/s41598-017-16476-1
PMCID: PMC5705714

Genes

ARMS2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison of two-year outcomes after photodynamic therapy with ranibizumab or aflibercept for polypoidal choroidal vasculopathy.PMID 29184088Read ↗

Two-year visual outcome of polypoidal choroidal vasculopathy treated with photodynamic therapy combined with intravitreal injections of ranibizumab.Semantic proximity Read ↗

Two-year visual outcome of ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.Semantic proximity Read ↗

Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.Semantic proximity Read ↗

Ethnic Differences on Long Term Outcomes of Polypoidal Choroidal Vasculopathy after Predominantly Bevacizumab Monotherapy.Semantic proximity Read ↗

Association of ARMS2 genotype with response to anti-vascular endothelial growth factor treatment in polypoidal choroidal vasculopathy.Semantic proximity Read ↗

Genetic Variants Affecting Anti-VEGF Drug Response in Polypoidal Choroidal Vasculopathy Patients: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Genetic variants in pigment epithelium-derived factor influence response of polypoidal choroidal vasculopathy to photodynamic therapy.Semantic proximity Read ↗

Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease?Semantic proximity Read ↗

The Moorfields AMD Database Report 2 - Fellow Eye Involvement with Neovascular Age-related Macular DegenerationSemantic proximity Read ↗

Extended Duration Anti-VEGF Therapy for Chorioretinal Vascular Diseases: Successes, Failures and ChallengesSemantic proximity Read ↗

Association of lesion size and visual prognosis to polypoidal choroidal vasculopathy.Semantic proximity Read ↗

Pharmacogenetic associations with long-term response to anti-vascular endothelial growth factor treatment in neovascular AMD patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.